What smart money is saying about AbCellera Biologics
ABCL
No fund has written a full thesis on AbCellera Biologics in our archive, but 2 fund letters report a position in it — most recently Acatis in October 2026.
Get an email when a fund buys, sells or pitches it
2
Reported positions
0
Bought
0
Sold
2
Letters
Position history
Between Q3 2026 and Q4 2026, 2 fund letters reported a position in AbCellera Biologics, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q4 2026 | 1 | 0 | 0 | 0 |
| Q3 2026 | 1 | 0 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions
- HoldsAcatisOctober 2026
Listed in Acatis’s reported holdings.
AbCellera Biologics - HoldsAcatisSeptember 2026
“Mr. Leber, the ACATIS Datini Valueflex Fonds gained almost nine percent in August. Was it due to the Bitcoin re- covery? Yes, but it was not the only reason.The portfo- lio contains more than 80 individual positions, of which 15 gained more than 21 percent in August. I like to compare it to a collection of springs - you never know which one will shoot up, and when. In August, it was the (mostly smaller) biotech companies - they contribu- ted more to the monthly performance than our crypto investments. The biggest ‚jumper‘ in this sense was AbCellera Biologics.”
AbCellera Biologics
Read the letters behind these AbCellera Biologics positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger